Great Point Partners LLC Has $18.95 Million Stock Holdings in Evolus, Inc. (NASDAQ:EOLS)

Great Point Partners LLC reduced its position in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 52.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,170,000 shares of the company's stock after selling 1,281,772 shares during the quarter. Evolus makes up about 5.6% of Great Point Partners LLC's holdings, making the stock its 4th largest position. Great Point Partners LLC owned about 1.85% of Evolus worth $18,954,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the company. Quest Partners LLC bought a new stake in shares of Evolus in the second quarter valued at approximately $43,000. Quarry LP bought a new stake in Evolus during the 2nd quarter valued at $54,000. ProShare Advisors LLC raised its holdings in Evolus by 9.9% during the 1st quarter. ProShare Advisors LLC now owns 11,542 shares of the company's stock valued at $162,000 after acquiring an additional 1,035 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Evolus during the third quarter worth $191,000. Finally, Profund Advisors LLC bought a new position in shares of Evolus in the second quarter worth $130,000. 90.69% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CFO Sandra Beaver sold 3,276 shares of the company's stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $14.98, for a total value of $49,074.48. Following the completion of the transaction, the chief financial officer now directly owns 148,502 shares in the company, valued at approximately $2,224,559.96. This represents a 2.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the business's stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $15.85, for a total value of $89,251.35. Following the completion of the sale, the chief marketing officer now owns 82,375 shares of the company's stock, valued at $1,305,643.75. The trade was a 6.40 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 6.10% of the company's stock.

Wall Street Analyst Weigh In

EOLS has been the topic of a number of recent research reports. HC Wainwright reissued a "buy" rating and set a $27.00 price objective on shares of Evolus in a report on Thursday, November 7th. Cantor Fitzgerald restated an "overweight" rating on shares of Evolus in a research report on Monday, September 16th. Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 target price on shares of Evolus in a report on Friday, September 13th. Finally, Barclays boosted their price target on shares of Evolus from $16.00 to $20.00 and gave the company an "overweight" rating in a research report on Friday, September 13th.

Evolus Price Performance

Shares of NASDAQ EOLS traded up $0.97 during midday trading on Wednesday, hitting $13.80. 801,513 shares of the company's stock were exchanged, compared to its average volume of 595,790. The business's fifty day moving average price is $15.42 and its two-hundred day moving average price is $13.86. The company has a market cap of $873.82 million, a price-to-earnings ratio of -14.10 and a beta of 1.31. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. Evolus, Inc. has a 12-month low of $9.32 and a 12-month high of $17.82.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.